August 26, 2016
Chugai Pharmaceutical said on August 25 that it has submitted an application seeking approval of a weekly dosage for Actemra (tocilizumab) in rheumatoid arthritis (RA) patients who inadequately respond to the currently approved every-other-week dosing regimen. According to the company,...read more